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Transforming growth factor–β (TGF-β) functions to suppress tumorigenesis in normal mammary tissues and early-
stage breast cancers and, paradoxically, acts to promote the metastasis and chemoresistance in late-stage breast
cancers, particularly triple-negative breast cancers (TNBCs). Precisely howTGF-β acquires oncogenic characteristics
in late-stage breast cancers remains unknown, as does the role of the endogenous mammalian target of rapamycin
(mTOR) inhibitor, Dep domain–containing mTOR-interacting protein (Deptor), in coupling TGF-β to TNBC
development and metastatic progression. Here we demonstrate that Deptor expression was downregulated in
basal-like/TNBCs relative to their luminal counterparts. Additionally, Deptor expression was 1) inversely correlated
with the metastatic ability of human (MCF10A) and mouse (4T1) TNBC progression series and 2) robustly repressed
by several inducers of epithelial-mesenchymal transition programs. Functional disruption of Deptor expression in
4T07 cells significantly inhibited their proliferation and organoid growth in vitro, as well as prevented their
colonization and tumor formation in the lungs ofmice. In stark contrast, elevated Deptor expressionwas significantly
associated with poorer overall survival of patients harboring estrogen receptor α–negative breast cancers.
Accordingly, enforced Deptor expression in MDA-MB-231 cells dramatically enhanced their 1) organoid growth in
vitro, 2) pulmonary outgrowth in mice, and 3) resistance to chemotherapies, an event dependent on the coupling of
Deptor to survivin expression. Collectively, our findings highlight the dichotomous functions of Deptor inmodulating
the proliferation and survival of TNBCs duringmetastasis; they also implicate Deptor and its stimulation of survivin as
essential components of TNBC resistance to chemotherapies and apoptotic stimuli.
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Transforming growth factor–β (TGF-β) is a multifunctional cytokine
that governs essentially all aspects of mammary epithelial cell (MEC)
biology, which coalesce in the proper maintenance of mammary gland
homeostasis and structural integrity [1,2]. Importantly, this pleio-
tropic cytokine exhibits bifurcating activities that manifest in its
suppression of mammary tumorigenesis in normal MECs and
early-stage breast cancers and, conversely, in the induction of disease
progression and metastasis in their late-stage counterparts [3–5]. This
functional metamorphosis is known as the “TGF-β Paradox,” whose
molecular underpinnings remain mysterious and a major barrier
toward effectively targeting the TGF-β pathway as a means to alleviate
breast cancer development and metastatic progression.
TGF-β governs the behaviors of normal and malignant MECs by
engaging the receptor Ser/Thr protein kinases, TGF-β type I (TβR-I)
and type II receptors, which coalesce in phosphorylating and activating
the latent transcription factors, Smad2 and Smad3, leading to their
nuclear accumulation with Smad4 and global alterations in gene
expression [5–7]. Collectively, TGF-β activities that are dependent on
the functions of Smad2/3 are referred to as canonical TGF-β signaling,
which is complemented by its ability to activate a variety of
noncanonical signaling systems that are independent of Smad2/3.
Included in this list of noncanonical TGF-β effectors are small GTPases
(e.g., RhoA, Rac1, and Cdc42), Mitogen-activated protein (MAP)
kinases (e.g., Extracellular signal-regulated kinases [ERKs], c-Jun
N-terminal kinases [JNKs], and p38 Mitogen-activated protein kinase
[MAPK]), Phosphoinositide 3-kinase (PI3K):AKT:mammalian target
of rapamycin (mTOR), Nuclear factor-kappa B (NF-κB):Cox-2, and
integrins and adhesion complexes [6,8]. Importantly, imbalances
between canonical and noncanonical TGF-β signaling are associated
with its acquisition of oncogenic and metastatic activities [3,5].
Canonical and noncanonical TGF-β signaling inputs also coalesce in
stimulating epithelial-mesenchymal transition (EMT), which endows
polarized epithelial cells with mesenchymal and invasive phenotypes
[5,9,10] and with stem cell–like properties [11–13]. The initiation of
EMT programs in breast carcinoma cells contributes to their metastasis,
as well as to their resistance to traditional chemotherapies, leading to
incurable disease relapse [14,15]. Thus, deciphering the molecular
mechanisms and functions of EMT programs driven by TGF-β may
provide new insights and therapies capable of improving overall survival
rates in patients with metastatic disease.
Recently, Dep domain–containing mTOR-interacting protein
(Deptor) has emerged as an important player during the development
and progression of human malignancies [16]. Functionally, Deptor
interacts physically with mTOR and is a natural antagonist of mTOR
complex (mTORCs) 1 and 2 [17], and as such, aberrant Deptor
expression promotes the activation of AKT, the induction of autophagy,
and the acquisition of chemoresistance [18,19]. Additionally, upregu-
latedDeptor expression associates with lymph node andmetastasis status
[20] and predicts for poor overall survival of cancer patients [20,21].
Interestingly, although elevated expression of Deptor coincides with the
appearance of metastatic phenotypes, this same event is sufficient to
inhibit the expression of Snail and its stimulation of EMTprograms [22],
suggesting that Deptor mediates both metastasis-suppressing and
metastasis-promoting activities in developing carcinomas, including
those of the breast. Given the parallels between the dichotomous
functions of Deptor and TGF-β in developing mammary tumors, our
objective was to determine whether TGF-β coupled to Deptor
expression during mammary tumorigenesis, and if so, how this eventtranspired and impacted the acquisition ofmetastatic and chemoresistant
phenotypes of breast cancers. Herein we demonstrate dual functions for
Deptor during the metastatic cascade, such that 1) downregulated
Deptor expression in primary tumors is essential for the acquisition of
EMT and invasive phenotypes coupled to cell cycle arrest and 2)
upregulated Deptor expression in metastatic lesions is essential for the
initiation of anti-apoptotic and chemoresistant activities dependent on
the induction of survivin expression.
Materials and Methods
Cell Lines and Reagents
Normal murine mammary gland cells (NMuMG), murine 4T1
cells, and human MCF7, MCF10A, MDA-MB-231, and
MDA-MB-468 cells were obtained from American Type Culture
Collection (ATCC) (Manassas, VA), while murine 67NR and 4T07
and human MCF10Ca1h and MCF10Ca1a were all obtained from
Dr Fred Miller (Wayne State University, Detroit, MI). We previously
described the expression of polyoma middle T antigen (PyMT) or
human β3 integrin in NMuMG cells [23,24], while those engineered
to express Twist were subjected to Vesicular stomatitis virus
glycoprotein (VSVG) retroviral transduction of pBabe (Addgene,
Cambridge, MA) and subsequent selection with puromycin (5 μg/ml)
as described previously [25]. Human MDA-MB-468 cells were
maintained in Dulbecco's modified Eagle's medium supplemented
with 10% FBS, while all additional cell lines were cultured as
described previously [26–28]. 4T07 and MDA-MB-231 cells were
engineered to stably express firefly luciferase by transfection with
pNifty-CMV-luciferase and selection with Zeocin (500 μg/ml;
Invitrogen, Carlsbad, CA). Deptor-deficient cells were produced by
pLKO.1-puro lentiviral transduction using a scrambled shRNA (i.e.,
nonsilencing shRNA) or two independent and verified Deptor-
specific shRNAs, all of which were obtained from Open Biosystems
(Lafayette, CO). Alternatively, Deptor overexpression was undertaken by
subcloning the human Deptor cDNA (Addgene) cloned into the
Gateway G418 destination vector (Life Technologies, Carlsbad, CA)
using the BamHI and XhoI restriction sites as follows: 1) forward
5′-CCGGCCGGATCCATGGACTACAAGGATGAC and 2) reverse
5′-CCGGCCCTCGAGTCAGCACTCTAACTCCTC. The selection
of stable polyclonal populations of Deptor-deficient NMuMG, 4T07,
MCF-7, orMDA-MB-231 cells was accomplished by continuous culture
of over a span of 14 days in puromycin (5 μg/ml), while Deptor-
expressing MDA-MB-231 cells were isolated following 14 days of
continuous culture inG418 (500μg/ml; EMDMillipore, Billerica,MA).
In all cases, the extent of Deptor deficiency or overexpression was
determined by immunoblot analysis for Deptor as described below.
Immunoblot Analyses
Immunoblot analyses were performed as previously described [29].
Briefly, parental and Deptor-manipulated murine and human breast
cancer cells were seeded into six-well plates (500,000 cells per well)
and allowed to adhere overnight. Cells were subsequently incubated
in the absence or presence of the pharmacological inhibitors described
in Supplementary Table 1. Afterward, detergent-solubilized whole-
cell extracts were prepared by lysing the cells in Buffer H/1% Triton
X-100 (50 mM β-glycerophosphate, 1.5 mM EGTA, 1 mM DTT,
0.2 mM sodium orthovanadate, 1 mM benzamidine, 10 μg/ml
leupeptin, and 10 μg/ml aprotinin, pH 7.3), and clarified whole-cell
extracts (30 μg/lane) were fractionated through 10% sodium dodecyl
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phoretically to nitrocellulose, and immunoblotted with the antibodies
described in Supplementary Table 2.
Semiquantitative Real-Time Polymerase Chain Reaction Analyses
Real-time polymerase chain reaction (PCR) studies were per-
formed as described previously [26,29]. Briefly, cells (500,000 cells
per well) were seeded overnight onto six-well plates and subsequently
stimulated with TGF-β1 (5 ng/ml) for 24 hours. Where indicated,
cells were treated with paclitaxel (Sigma, St. Louis, MO; 50 nM) and
doxorubicin (Sigma; 50 nM). Afterward, total RNA was isolated
using the RNeasy Plus Kit (Qiagen, Germantown, MD) and reverse
transcribed using the iScript cDNA Synthesis System (Bio-Rad,
Hercules, CA). Semiquantitative real-time PCRwas conducted using
iQ-SYBR Green (Bio-Rad) according to the manufacturer’s
recommendations. In all cases, differences in RNA concentration
for individual genes were normalized to their corresponding
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA
signals. The oligonucleotide primer pairs used are provided in
Supplementary Table 3.
Apoptosis Assay
NMuMG and MDA-MB-231 derivatives were seeded in serum-
free media onto 96-well plates (10,000 cells per well). NMuMG cells
were allowed to adhere overnight, while MDA-MB-231 cells were
cultured over poly-HEMA–coated plates. Seventy-two hours later,
the extent of caspase-3/7 activity was quantified using the
Caspase-Glo 3/7 luminescence assay system according to the
manufacturer’s recommendations (Promega, Madison, WI).
Invasion Assay
The ability of 4T07 cells (50,000 cells per well) to invade
reconstituted basement membranes was measured using modified
Boyden chambers as previously described [26] and using 2% serum as
a chemoattractant.
Three-Dimensional Organotypic Cultures
Three-dimensional (3D) organotypic cultures using the “on-top”
method were performed as described [29]. Briefly, cells (2000 cells
per well) were cultured in 96-well plates onto Cultrex cushions
(50 μl/well; Trevigen, Gaithersburg, MD) in complete media
supplemented with 5% Cultrex. Organoid growth was monitored
by bright-field microscopy [30] or by longitudinal bioluminescence
growth assays as described previously [31].
Anoikis Assay
Anoikis assays were performed as described [32]. Briefly, control
(MT) and Deptor-expressing MDA-MB-231 or 4T07 cells were
cultured over poly-HEMA–coated plates in serum-free medium. The
cells were collected 72 hours after plating, at which point they were
prepared for survivin immunoblot analyses.
Annexin V Staining
Paclitaxel (50 nM) and doxorubicin (50 nM) treated
MDA-MB-231 derivative cells were trypsinized and resuspended in
binding buffer (1 × 106 cells/ml). Subsequently, 100 μl of each
treatment group was stained with Annexin V–fluorescein isothiocy-
anate (BD Biosciences, San Jose, CA) for 15 minutes at room
temperature, at which point 400 μl of binding buffer was added to the
stained cells before analyzing Annexin V positivity by flow cytometry.Tumor Growth and Bioluminescence Imaging
Luciferase-expressing parental (scram) orDeptor-deficient 4T07 cells
(50,000 cells per mouse) or parental (MT) or Deptor-overexpressing
MDA-MB-231 cells (1.5 × 106 cells per mouse; n = 5) were injected
into the lateral tail vein of female BALB/c or nude mice, respectively.
Afterward, pulmonary outgrowth was monitored and quantified using
intravital bioluminescence imaging as described [33]. All animal studies
were performed in accordance with the Institutional Animal Care and
Use Committee for Case Western Reserve University.
Results
Deptor Expression Is Decreased in Aggressive Breast Cancers
Although elevated mTOR activity has been reported in breast cancers
[34,35], the role that Deptor plays in mediating this event during
mammary tumorigenesis remains to be fully elucidated. As such, we
performed Oncomine microarray expression analyses and found Deptor
expression to be significantly downregulated in breast cancers as
compared to normal breast tissue (Figure 1A). Accordingly, Deptor
expression was reduced in metastatic 4T1 cells relative to their indolent
67NR and dormant 4T07 counterparts (Figure 1B). Next, we addressed
whether this trend in Deptor expression also occurred in human breast
cancer cell lines. As shown in Figure 1C, Deptor expressionwas noticeably
absent in low-grade human MCF10aCa1h and high-grade human
MCF10aCa1a cells relative to their indolent human MCF10aT1K
counterparts. Likewise, Deptor expression was also dramatically reduced
in metastatic MDA-MB-231 cells as compared to nonmetastatic MCF7
cells (Figure 1D). Collectively, these findings suggest that diminished
Deptor expression is characteristic of invasive breast cancers.
Deptor Expression Is Regulated by Estrogen Receptor α
Given the differences in Deptor expression that exist between the
estrogen receptor α (ERα)–positive MCF7 cells and ERα-negative
MDA-MB-231 cells (Figure 1D), we surveyedDeptormRNA expression
in additional breast cancer cell lines categorized as being positive (e.g.,
luminal subtypes) or negative (e.g., basal-like/triple-negative subtypes) for
expression of ERα. As shown in Figure 2A, Deptor expression was
significantly decreased in ERα-negative breast cancers (e.g., basal-like/
triple-negative) relative to those classified as ERα-positive (e.g., luminal).
Indeed, upon examination of the Deptor promoter sequence, we
discovered two ER-binding elements (data not shown), suggesting that
the expression of Deptor mRNAmay be regulated by ERα. Accordingly,
Oncomine analyses showed that Deptor expression is indeed elevated and
associated with that of ERα (Figure 2B). Moreover, treating MCF7 cells
with the ERα antagonist tamoxifen or fulvestrant (ICI) decreased Deptor
expression (Figure 2C), while administration of the ERα agonist estradiol
significantly increased Deptor expression in MCF-7 cells (Figure 2D).
Finally, in considering the role of TGF-β in driving breast cancer
pathogenesis [4–6], we monitored Deptor expression in MCF7 cells
before and after their stimulation with TGF-β. As shown in Figure 2E,
TGF-β treatment of MCF7 cells failed to affect their expression of either
ERα or Deptor. Collectively, these findings suggest that basal-like/
triple-negative breast cancers (TNBCs) express significantly decreased
levels of Deptor that may reflect their loss of ERα expression.TGF-β Downregulates Deptor Expression through a Smad3-
Dependent Pathway
Previous studies observed ERα expression to be downregulated in
response to TGF-β [36]. Accordingly, we too observed TGF-β to
Figure 1. Deptor expression is decreased in aggressive breast cancers. (A) Oncomine data examining Deptor expression in normal and
malignant cancer tissues using Richardson Breast 2 data set. (B) Deptor expression is dramatically reduced in metastatic 4T1 cell lines as
comparedwith their nonmetastatic 67NRand4T07 counterparts. (C) Deptor expression is dramatically reduced inmalignantMCF10Ca1h and
MCF10Ca1a cells as compared to their weakly tumorigenicMCF10aT1K counterpart. (D) Deptor expression is noticeably absent in basal-like/
TNBCMDA-MB-231 cells as compared to luminal MCF7 cells. Immunoblots in B to D are representative of three independent experiments.
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(Figure 3A), which occurs concomitantly with a dramatic reduction
of Deptor mRNA (Figure 3B) and protein (Figure 3C). Since the
pathophysiology of TGF-β reflects its activation of both canonical
and noncanonical effector molecules [6,8], we next sought to
elucidate which branch of the TGF-β signaling system elicits
diminished Deptor expression in normal and malignant MECs. To
do so, we used pharmacological inhibitors against Smad3 (SIS3; [37])
and p38 MAPK (SB203580; [38]) in conjunction with TGF-β
administration. In doing so, we observed SIS3 to antagonize the
ability of TGF-β to downregulate Deptor expression in nontumori-
genic NMuMG cells (Figure 3D). Interestingly, the coupling of
TGF-β to downregulated Deptor expression was prevented by
antagonism of both p38 MAPK and Smad3 in the 4T1 cells
(Figure 3E), suggesting that both branches of the TGF-β signaling
system drive the loss of Deptor expression in ERα-negative breast
cancer models. We also examined the coupling of TGF-β to Deptor
expression in human MDA-MB-468 cells, which lack expression of
both ERα and Smad4. Interestingly, Deptor expression was
unaffected in TGF-β–treated MDA-MB-468 cells (Figure 3F),
confirming the requirement of Smad-dependent signals in downreg-
ulating Deptor expression. Finally, we inhibited TGF-β signaling by
treating 4T1 cells with two distinct TGF-β antagonists: 1) TβR-I type
II inhibitor, which specifically inhibits Alk5 [39], and 2) SB431542,
which specifically inhibits Alk4, Alk5, and Alk7 [40]. Importantly,
administration of either TβR-I inhibitor induced Deptor expression
in 4T1 cells (Figure 3G), suggesting that autocrine TGF-β signaling
serves in driving constitutive down-regulation of Deptor expression in
basal-like/TNBCs. Collectively, these findings demonstrate that the
ability of TGF-β to downregulate Deptor expression in normal and
malignant cells is context-specific and dependent on loss of
ERα expression.Loss of Deptor Expression Is Associated with EMT Programs
The loss of ERα expression or function elicits EMT programs in
MECs [41,42], as does activation of the TGF-β signaling system
[5,9,10]. As such, we monitored the extent to which Deptor
expression is downregulated in NMuMG cells stimulated to undergo
EMT programs by TGF-β or by overexpression of either PyMT,
Twist, or β3 integrin [23,24,43]. As expected, TGF-β stimulated
NMuMG cells to acquire EMT phenotypes (Figure 4A), as well as
downregulated Deptor expression (Figure 4B). Additionally,
transgenic expression of PyMT (Figure 4, A and B), Twist
(Figure 4, C–E ), or β3 integrin (Figure 4, F and G ) also elicited
EMT programs and downregulated expression of Deptor in
NMuMG cells, events that were greatly enhanced by administration
of TGF-β. Thus, these findings implicate diminished Deptor
expression as a component of EMT programs in MECs. However,
these analyses fail to address whether Deptor deficiency is sufficient to
elicit EMT reactions in breast cancer cells. To answer this question,
we rendered 4T07 and MCF7 cells deficient in Deptor expression
using two independent murine and human shRNAs against Deptor
mRNA. As expected, Deptor deficiency elicited elevated activation of
S6 kinase (S6K) in 4T07 (Supplementary Figure 1A) and MCF7
(Supplementary Figure 1D) cells, as well as produced an inconsistent
and less robust stimulation of AKT (data not shown). Moreover,
Deptor deficiency was sufficient to promote partial EMT-like
phenotypes in both 4T07 and MCF7 cells (Supplementary Figure
1, B and E), particularly with respect to down-regulation of the
epithelial markers, E-cadherin and CK19 (Supplementary Figure 1, C
and E). Interestingly, Deptor inactivation failed to impact the
expression of the mesenchymal markers, β3 integrin and vascular
endothelial growth factor (data not shown), suggesting a preferential
role of Deptor in regulating epithelial gene expression patterns during
EMT. Finally, we determined whether Deptor down-regulation
Figure 2. Deptor expression is regulated by ERα. (A) Deptor mRNA expression is significantly lower in ERα-negative (ERα-neg) breast
cancer subtypes as compared to ERα-positive (ERα-pos) breast cancer subtypes as determined by the Broad-Novartis Cancer Cell Line
Encyclopedia. Inset shows mean (±SEM) of Deptor mRNA expression in ERα-negative and ERα-positive breast cancer cells.
(B) Oncomine analyses associated elevated Deptor mRNA expression levels with that of ERα-positive breast cancers using the Waddell
Breast data set. (C) MCF7 cells were treated with tamoxifen (0.1 nM) or fulvestrant (ICI, 0.1 nM) for 4 days, at which point the cells were
harvested and probed for Deptor expression by immunoblot analysis. MCF7 cells were treated with either estradiol (10 nM) or TGF-β1
(5 ng/ml) for 4 days before monitoring Deptor or ERα expression by immunoblot analysis. Immunoblots in C to E are representative of
three independent experiments.
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as they traverse this transdifferentiation process [44]. As shown in
Supplementary Figure 2A, Deptor expression was unaffected in
NMuMG cells cultured under several stress conditions, including
growth factor deprivation or administration of either 5-fluorouracil or
hydrogen peroxide. Along these lines, Deptor deficiency failed to
impact the invasiveness of 4T07 cells (Supplementary Figure 2B), nor
did this same cellular event impact the activation status of S6K and
AKT in NMuMG cells (Supplementary Figure 2C), or their survival
upon growth factor deprivation (Supplementary Figure 2D).
Collectively, these findings demonstrate that EMT programs repress
Deptor expression, an event that is sufficient to elicit partial EMT
phenotypes and altered epithelial gene expression patterns that are
uncoupled from motility and programmed cell death pathways in
normal and malignant MECs.Deptor Deficiency Inhibits Breast Cancer Growth Both In
Vitro and In Vivo
In addition to exhibiting alterations in cell morphology and
motility, cells acquiring EMT phenotypes also display reducedcapacities to proliferate [4]. As such, we examined the role of Deptor
in regulating cell growth and proliferation. As shown in Figure 5, A
and B, Deptor deficiency significantly inhibited DNA synthesis in
NMuMG and MCF7 cells, as well as in 4T07 cells propagated in 2D
(data not shown) and 3D cultures (Figure 5C). To examine the role of
Deptor in vivo, we inoculated parental (scram) and Deptor-deficient
4T07 cells into the lateral tail vein of BALB/c mice. In accordance
with our in vitro results, Deptor-deficient 4T07 cells grew less
efficiently in the lungs of mice as compared to their parental (scram)
counterparts (Figure 5D). Indeed, large tumor nodules were readily
apparent by gross anatomy (Figure 5E) and Hematoxylin & Eosin
(H&E) staining (Figure 5F) of the lungs of mice inoculated with
parental (scram) 4T07 cells, an event that was noticeably absent in the
lungs of mice inoculated with Deptor-deficient 4T07 cells. Ex vivo
culturing of these 4T07 derivatives demonstrated that Deptor
deficiency was retained in the shDeptor group, whereas the parental
(scram) group exhibited robust Deptor expression (Figure 5G). Taken
together, these findings suggest that Deptor down-regulation elicits
diminished proliferative capacity associated with EMT programs in
normal and malignant MECs, thereby inhibiting the metastatic
outgrowth of breast cancer cells in preclinical settings.
Figure 3. TGF-β downregulates Deptor expression through a
Smad3-dependent pathway. (A) NMuMG cells were treated with
TGF-β1 (5 ng/ml) as indicated and subsequently subjected to anti-ERα
immunoblot analysis. Immunoblots are representative of three
independent experiments. TGF-β1 (5 ng/ml for 48 hours) down-
regulates the expression of Deptor mRNA (B) and protein (C) in
NMuMG cells. Data are mean (±SE; *P b .007). NMuMG (D) and 4T1
(E) cells were stimulated with TGF-β1 for 48 hours in the absence or
presence of the p38 MAPK inhibitor, SB203580 (p38; 10 μM), or the
Smad3 inhibitor, SIS3 (10 μM). Data are representative of three
independent experiments. (F) 4T1cellswere cultured in the absenceor
presence of the TβR-I antagonist TβR-I type II inhibitor (10 μg/ml) or
SB431452 (SB; 10 μM). Immunoblots are representative of three
independent experiments. (G) MDA-MB-468 cells were stimulated
with TGF-β1 (5 ng/ml) for 4 days. Immunoblots are representative of
three independent experiments.
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Metastatic Breast Cancers
The aforementioned findings led us to hypothesize that Deptor
down-regulation is associated with EMT and the egress of breast cancer
cells out of the primary tumor and that the re-expression of Deptor at
metastatic lesions facilitates their efficient outgrowth. As an initial test of
this intriguing hypothesis, we discovered that high levels of Deptor
expression correlated with poor overall survival in patients harboring
ERα-negative breast cancers (Figure 6A). Interestingly, engineering
MDA-MB-231 cells to overexpress Deptor resulted in a dramatic
decrease inAKT activation concomitantwith increased activation of S6K
(Figure 6B). As compared to their parental counterparts, Deptor-
expressingMDA-MB-231 cells exhibited significantly greater outgrowth
in 3D organotypic cultures (Figure 6C) and in the lungs of nude mice
inoculated intravenously with these TNBCs as determined
by bioluminescence imaging (Figure 6D), by gross anatomy
(Figure 6E, top), and by H&E staining (Figure 6E, bottom). As shown
in Figure 6F, engineered expression of Deptor was retained and readily
apparent in pulmonary metastases derived from Deptor-expressing
MDA-MB-231 cells, supporting the conclusion that Deptor expression
is necessary for and drives the metastatic outgrowth of ERα-negative
breast cancer cells both in vitro and in vivo.Deptor Promotes Breast Cancer Survival through Coupling to
Survivin Expression
It should be noted that parental MDA-MB-231 cells exhibit a
rapid and sharp decline in their bioluminescent signals when
inoculated into the lateral tail veins of mice, an event that was
significantly reduced in their Deptor-expressing counterparts
(Figure 6D), suggesting that one mechanism whereby elevated
Deptor expression may enhance pulmonary outgrowth is by
preventing apoptosis. In support of this hypothesis, the magnitude
of anoikis and caspase-3/7 activation exhibited by nonadherent
MDA-MB-231 cells was significantly reduced by Deptor overexpres-
sion (Figure 7A), which also resulted in the robust expression of
survivin both in vitro (Figure 7B) and in vivo (Figure 7C).
Importantly, the linkages between Deptor and elevated survivin
expression were also observed in murine 4T07 cells engineered to
stably overexpress Deptor (Figure 7D). We also determined the extent
to which elevated Deptor expression contributes to chemotherapy
resistance. In doing so, Oncomine analysis demonstrated that
elevated Deptor expression is associated with paclitaxel resistance
(Figure 7E). Unlike their parental counterparts, Deptor-expressing
MDA-MB-231 cells failed to activate caspase3/7 (Figure 7F) and
dramatically upregulated their expression of survivin (Figure 7G) in
response to paclitaxel administration. Finally, to determine whether
elevated survivin expression mediated Deptor-induced chemoresis-
tance, we rendered Deptor-expressing MDA-MB-231 cells deficient
in survivin expression (Figure 7H) and subsequently monitored their
sensitivity to paclitaxel and doxorubicin. As shown in Figure 7I,
inactivation of survivin expression inactivated the pro-survival
function of Deptor and, consequently, sensitized MDA-MB-231
cells to the anticancer activities of paclitaxel and doxorubicin as
measured by significantly elevated Annexin V staining. Collectively,
these findings demonstrate that the ability of Deptor to promote
TNBC survival is mediated through upregulated expression of
survivin, which contributes to the inherent chemoresistance
of TNBCs.
Discussion
The role of mTOR in human breast cancers has been well
characterized, leading to the development and implementation of
mTOR inhibitors as potential targeted therapies against TNBCs [45].
Despite the intense interest in deploying mTOR inhibitors in the
treatment of human mammary tumors, comparatively little informa-
tion exists related to the precise role played by the endogenous
mTOR inhibitor, Deptor, during breast cancer development and
metastatic progression. Here, we aimed to determine how Deptor
expression was regulated by TGF-β and how these events coalesced to
affect breast cancer metastasis, particularly in TNBCs. In doing so, we
observed Deptor expression to be governed by two major signaling
systems in MECs: TGF-β, which repressed Deptor expression, and
ERα, which induced Deptor expression. With respect to the former
pathway, we demonstrated the ability of Smad3 to suppress Deptor
expression in normal and malignant MECs (Figure 3), presumably
through TGF-β inhibitor elements [46]. Although future studies
need to determine the extent to which the loss of Deptor expression is
mediated either directly by Smad3 or indirectly by a distinct
Smad3-inducible gene, we nevertheless established the necessity for
noncanonical TGF-β signaling and its coupling to p38 MAPK in
maximally suppressing Deptor expression specifically in late-stage
breast cancers, not their normal counterparts. Interestingly, the
Figure 4. Loss of Deptor expression is associated with EMT programs. Deptor expression was evaluated in different models of EMT
induction: (A and B) PyMT (n = 3), (C–E) Twist (n = 3), and (F and G) β3 integrin (n = 2). In all cases, initiation of EMT programs was
sufficient to downregulate Deptor expression. Photomicrographs are representative images obtained using a 10× objective.
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MECs treated with TGF-β resembles similar disturbances between
the canonical and noncanonical TGF-β pathways during mammary
tumorigenesis [5,6], thereby implicating Deptor as a dichotomous
regulatory molecule during the development of metastatic disease.
With respect to ERα and its regulation of Deptor expression, we
observed the presence of two estrogen response elements (EREs)
within the Deptor promoter (data not shown), suggesting that ERα
induces Deptor expression at the level of transcription. Accordingly,
treating MCF7 cells with estradiol significantly elevated Deptor
expression, while pharmacological inactivation of ERα expression or
activity significantly depressed Deptor expression (Figure 2). Inter-
estingly, ERα has been documented to antagonize TGF-β signaling,
doing so by interacting physically with Smad3 and inhibiting its
activation in response to TGF-β [47]. These findings point toward a
novel and dynamic post-transcriptional mechanism that enables ERα
to modulate the downregulated expression of Deptor induced byTGF-β:Smad3 in ERα-positive tumors, an event that is lacking in
their ERα-negative counterparts and likely contributes to their disease
progression stimulated by TGF-β. Future studies need to better
define post-transcriptional mechanisms coupled to Deptor expression
across distinct breast cancer subtypes, particularly distinct subtypes of
TNBCs and their varied sensitivities to chemotherapies [48,49].
Deptor was originally identified as an endogenous inhibitor of
mTORCs 1 and 2, whose constitutive activation in Deptor-deficient
cells elicits the robust activation of S6K, AKT, and Serum and
glucocorticoid regulated-kinase 1 (SGK1) necessary in driving
carcinoma growth and survival. Interestingly, this same study also
found Deptor overexpression to promote constitutive activation of
PI3K and AKT, leading to enhanced cell survival [17]. In stark contrast,
we observed Deptor deficiency to elicit a robust stimulation of S6K
solely in malignant MECs; however, this same cellular condition
produced little to no effect on the activation status of ATK, as did the
dramatic overexpression of Deptor in human MDA-MB-231 cells.
Figure 5. Deptor deficiency inhibits breast cancer growth both in vitro and in vivo. Deptor deficiency (sh1 and sh2) inhibits DNA synthesis in
NMuMG (A),MCF7 (B), and 4T07 (C) cells as determined by [3H]thymidine incorporation. Data aremean (±SEM; n=3; *P b .05), except for C
(n=2). (D) Parental (scram) andDeptor-deficient (shDeptor) 4T07 cellswere inoculated into the lateral tail vein of syngeneicBALB/cmice, and
pulmonary tumor growth was monitored by longitudinal bioluminescence imaging as indicated. Data are mean (±SEM; n = 5; *P b .0005,
**P b .03). Lungswere isolated at the time of sacrifice to visualize surface (E, arrowheads) and embeddedmetastases by H&E staining (F). (G)
Lungs were dissociated into single cells and cultured ex vivo to monitor Deptor expression by immunoblot analysis, which demonstrated
maintenance of Deptor deficiency in pulmonary-derived 4T07 cells.
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remain to be fully elucidated, it is tempting to speculate that mammary
carcinomas lack expression of additional scaffolding molecules operant
in couplingDeptor to AKT activation, an event that appears to transpire
in a cell type–specific manner. More intriguingly, we found Deptor
deficiency to strongly inhibit breast cancer cell proliferation (Figure 5),
which contrasts sharply with the strong survival signals produced by
Deptor overexpression (Figure 6). Indeed, these disparate activities of
Deptor may reflect its coupling to mTOR-dependent and mTOR-
independent pathways in developing and progressing mammary
tumors. For instance, Deptor contains a PDZ domain [17] that can
1) homodimerize or heterodimerize with other PDZ domain–
containing proteins [50], particularly those localized with junctional
complexes, such as zona occludens-1 (ZO-1) [51], and 2) form
lipid-protein complexes by binding lipid molecules, particularly
phosphoinositides [52]. Therefore, we postulate that in addition to
its roles in governing mTOR function and signaling, Deptor alsoserves in maintaining the junctional integrity and polarity of MECs
(Figure 3 and Supplementary Figure 1) and in regulating lipid
metabolism, both of which become dysregulated during mammary
tumorigenesis [53,54].
In accordance with the aforementioned reasoning, we (Figure 3
and Supplementary Figure 1) and others [55] have associated
diminished Deptor expression with the acquisition of EMT
phenotypes in malignant MECs (Figure 1). Likewise, Chen and
colleagues [22] found Deptor deficiency to promote the activation of
AKT and Snail expression in A549 lung carcinoma cells, leading to
their stimulation of EMT programs. Remarkably, Deptor deficiency
also functioned as a potential inhibitor of cell proliferation,
particularly in post-EMT breast cancer cells. It should be noted
that EMT programs promote the selection and expansion of breast
cancer cells that exhibit characteristics of cancer stem cells [11], which
are poorly proliferative as compared to non–cancer stem cells [56].
Collectively, these findings suggest that Deptor expression suppresses
Figure 6. Deptor expression is necessary for pulmonary outgrowth of metastatic breast cancers. (A) ERα-negative breast cancer patient
survival is significantly longer if Deptor expression is low as compared to tumors housing high Deptor expression. (B) Monitoring changes
in AKT and S6K expression and activation in MDA-MB-231 cells engineered to overexpress Deptor. (C) Parental (MT) or Deptor-expressing
MDA-MB-231 cells were propagated in 3D organotypic cultures for 6 days, during which time organoid growth was monitored
longitudinally by bioluminescence on the indicated days. Data are themean (±SE; n= 3; *P b .03). (D) Parental (MT) or Deptor-expressing
MDA-MB-231 cells were injected into the lateral tail vein of nude mice. Pulmonary tumor growth was monitored by longitudinal
bioluminescence imaging at the indicated times (n = 5; *P b .05). (E) Gross anatomy and H&E staining of lungs bearing parental (MT) or
Deptor-expressing MDA-MB-231 tumors. (F) Immunohistochemical staining of Deptor in parental (MT) and Deptor-expressing
MDA-MB-231 pulmonary lesions.
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consistent with the down-regulation of Deptor in luminal breast
cancer stem cells [57].
Although the mechanisms that enable Deptor to suppress the
development of cancer stem cells remains to be fully elucidated,
similar uncertainty relates to precisely how late-stage breast cancers
circumvent the loss of Deptor, particularly at sites of metastasis. For
example, metastatic MDA-MB-231 and MCF10CA1a breast cancer
cells harbor activating mutations in Ras [55] and PI3K [58],
respectively, which may aid in offsetting Deptor deficiency. Likewise,
restoration of Deptor expression enhances the growth of
MDA-MB-231 cells (Figure 6), indicating that Deptor fulfills two
distinct roles during mammary tumorigenesis. First, initiation of
EMT programs alleviates Deptor expression, resulting in cell cyclearrest and in transitioning breast carcinoma cells as they disseminate
to distant locales. Upon colonization of a metastatic site, we propose
that low levels of Deptor expression contribute to metastatic
dormancy, a phenotype that is overcome upon re-expression of
Deptor and the initiation of mesenchymal-epithelial transitions
necessary to complete the metastatic cascade.
Finally, the mechanism whereby Deptor induces survivin
expression remains to be elucidated. A previous study observed
TGF-β to downregulate survivin expression in response to Smad2/
3-mediated hypophosphorylation of the tumor suppressor, Rb [59];
however, the extent to which Deptor expression modulates and/or
inactivates these is currently unknown. Nevertheless, rendering
Deptor-expressing MDA-MB-231 cells deficient in survivin expres-
sion clearly enhanced the sensitivity of these TNBCs to paclitaxel and
Figure 7. Deptor promotes breast cancer survival through coupling to survivin expression. (A) Caspase-Glo 3/7 analyses were performed
to monitor the extent of anoikis and caspase-3/7 activation in control (MT) and Deptor-expressing MDA-MB-231 cells. Data are the mean
(±SE; n = 3; *P b .02). (B) Deptor expression induces that of survivin in MDA-MB-231 cells cultured over poly-HEMA–coated plates.
Immunoblots are representative of three independent experiments. (C) Immunohistochemical staining of survivin in pulmonary lesions
produced by parental (MT) and Deptor-expressing MDA-MD-231 cells inoculated into mice used in Figure 6. (D) Deptor expression
induces that of survivin in 4T07 cells cultured over poly-HEMA–coated plates. Immunoblots are representative of two independent
experiments. (E) Oncomine data correlating Deptor expression to paclitaxel responsiveness using Barretina Breast Cancer Cell
Line. (F) Caspase-Glo 3/7 analyses of paclitaxel-treated (50 nM) control (MT) and Deptor-expressingMDA-MB-231 cells. Data are themean
(±SEM; n = 2; *P b .002). (G) Paclitaxel treatment significantly induces survivin mRNA expression in Deptor-expressing MDA-MB-231
cells as compared to their parental counterparts. Data are the mean (±SEM; n = 4; *P b .04). (H) MDA-MB-231 cells were depleted of
survivin expression using two independent lentiviral shRNAs against survivin (shSv1 and shSv2). (I) Annexin V–fluorescein isothiocyanate
staining of parental (MT), Deptor-expressing (Deptor), or Deptor-expressing/survivin-deficient (Deptor shSv1/2) MDA-MB-231 cells treated
with either paclitaxel (50 nM) or doxorubicin (50 nM) as indicated. The top panels show representative histograms obtained in two
independent experiments, while the bottom panel shows the mean (±SEM; n = 2; *P b .05).
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expression likely engenders chemoresistance in TNBCs in part
through the ability of survivin to regulate apoptosis [60,61], mitosis
[62], and autophagy [60]. Future studies need to delineate how
Deptor drives survivin expression in late-stage TNBCs, as well as todetermine which survivin pathways elicit chemoresistance in
recurrent disease settings. Collectively, our findings implicate Deptor
as an essential player during TNBC development and metastatic
progression and as a potential biomarker to predict for resistance to
standard-of-care chemotherapies.
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